Fate Therapeutics, Inc. — Income Charts
2 years of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$7M
R&D
$108M
D&A
$13M
Operating Income
$-148M
EBITDA
$-135M
Interest Expense
—
Interest Income
$11M
Tax Provision
$2K
Net Income
$-136M
Operating Margin
-2222.4%
Net Margin
-2051.1%
Deferred Tax Liabilities
$388M
DTA Valuation Allowance
$388M
Tax Credit Carryforwards
$67M
NOL Carryforwards
$187M
ETR (Continuing Operations)
0.0%
ETR Federal Statutory
21.0%
ETR State + Local (pp)
7.6%
Operating Lease Cost
$15M
Revenue YoY Variation
-51.2%
Income YoY Variation
29.8%